Pcn317 Validation of a Standard Set of Patient-Centered Outcomes for Lung Cancer in Spain

Abstract

checked if the regimens used in 2018 aligned with clinical guidelines and best clinical practices and conducted an expert review on the regimens' prescription rates. Results: Data set included 11,190 cases of antineoplastic pharmacotherapy both in inpatient hospitals and in day inpatient units. 3,327 cases (29.7%) carried no information on the regimen, in 940 cases (8.4%) prescribed regimens did not aligned with the clinical guidelines. The most frequently prescribed regimens are anti-PD-1 therapy (40.8% of cases), decarbazine alone (27.1%), interferon-alfa (9.6%). Expert estimation on best practice usage of the regimens are 47.8% for anti-PD-1, 0.5% for decarbazine alone, 33.1% for interferon-alfa. Conclusions: Preliminary results show rather low data encoding quality but we expect it to improve when hospitals get more experience with the new DRG system. Clinical specialists do not always take into account clinical guidelines or best clinical practices and might need more training. This can be made possible with the help of additional financial resources set aside to support the government cancer program.